BioInfra Co., Ltd.
Sang Deuk Lee, Ph.D.
(owns 43.0% of share/2023 4Q)
May 2007
23.9 billion Won
470 billion Won
116
301.3 billion Won
Clinical study CRO business
YU&Infra Co., Ltd.(50%)
Heungdeok U-Tower, Giheung-gu, Yongin-si
Seoul National University, Ph.D. in Pharmacy
Principal Research Engineer, Dong-A Pharmaceutical Co., Ltd. / Clinical Department team leader
Vice president, The Korean Society of Pharmaceutical Sciences and Technology / Honorary President
CEO, BioInfra Co., Ltd.